Abstract
Autophagy is an evolutionary conserved process by which cells recycle intracellular materials to maintain homeostasis in different cellular contexts. Under basal conditions it prevents accumulation of damaged proteins and organelles; during starvation, autophagy provides cells with sufficient nutrients to survive. Sphingolipids are a family of bioactive molecules modulating vital cellular functions such as apoptosis, cell cycle arrest or proliferation. Besides these functions, some sphingolipids like ceramide, sphingosine- 1-phosphate or gangliosides have been described to promote autophagy in several cancer cell lines. Current evidence supports the notion that induction of autophagic cell death can halt tumorigenesis. Of interest, some chemotherapeutic agents used for the treatment of hematological malignancies trigger the production of endogenous sphingolipids with pro-autophagic effects. In this review we describe the regulation and functions of the sphingolipid-induced autophagy and the tight relationship with the cancer cell response to current chemotherapeutic regimens.
Keywords: Sphingolipid, autophagy, ceramide, sphingosine-1-phosphate, cancer, hematological malignancies, UPS, ATG, PKB, JNK, Gangliosides, Mtor
Anti-Cancer Agents in Medicinal Chemistry
Title: Regulation of Autophagy by Sphingolipids
Volume: 11 Issue: 9
Author(s): Carmen Bedia, Thierry Levade and Patrice Codogno
Affiliation:
Keywords: Sphingolipid, autophagy, ceramide, sphingosine-1-phosphate, cancer, hematological malignancies, UPS, ATG, PKB, JNK, Gangliosides, Mtor
Abstract: Autophagy is an evolutionary conserved process by which cells recycle intracellular materials to maintain homeostasis in different cellular contexts. Under basal conditions it prevents accumulation of damaged proteins and organelles; during starvation, autophagy provides cells with sufficient nutrients to survive. Sphingolipids are a family of bioactive molecules modulating vital cellular functions such as apoptosis, cell cycle arrest or proliferation. Besides these functions, some sphingolipids like ceramide, sphingosine- 1-phosphate or gangliosides have been described to promote autophagy in several cancer cell lines. Current evidence supports the notion that induction of autophagic cell death can halt tumorigenesis. Of interest, some chemotherapeutic agents used for the treatment of hematological malignancies trigger the production of endogenous sphingolipids with pro-autophagic effects. In this review we describe the regulation and functions of the sphingolipid-induced autophagy and the tight relationship with the cancer cell response to current chemotherapeutic regimens.
Export Options
About this article
Cite this article as:
Bedia Carmen, Levade Thierry and Codogno Patrice, Regulation of Autophagy by Sphingolipids, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/187152011797655131
DOI https://dx.doi.org/10.2174/187152011797655131 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Enhanced Floating and Intragastric Release of 5-Flourouracil through Sesame Oil Entrapped Gellan Composite Hydrogel Beads
Current Drug Therapy Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia
Current Cancer Drug Targets Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells
Current Immunology Reviews (Discontinued) Mesenchymal Stem Cell-Based Therapy for the Treatment of Type 1 Diabetes Mellitus
Current Stem Cell Research & Therapy Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Analysis of Drug Transport Kinetics in Multidrug-resistant Cells: Implications for Drug Action
Current Medicinal Chemistry